Literature DB >> 2614228

Auditory and vestibular findings in Waardenburg's type II syndrome.

M Hildesheimer1, Z Maayan, C Muchnik, M Rubinstein, R M Goodman.   

Abstract

A group of 33 patients with the autosomal dominant form of Waardenburg Type II syndrome underwent hearing and vestibular examination. A bilateral, symmetrical, sensorineural hearing loss was found in 51 per cent of the tested subjects. The severity of hearing loss varied from mild to severe. Strong evidence indicated the possible progressive nature of the hearing loss. Concerning the frequency of vestibular findings, the study highlights the frequent divergence between cochlear and vestibular involvement.

Entities:  

Mesh:

Year:  1989        PMID: 2614228     DOI: 10.1017/s0022215100111181

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  4 in total

Review 1.  Genetic insights, disease mechanisms, and biological therapeutics for Waardenburg syndrome.

Authors:  Sida Huang; Jian Song; Chufeng He; Xinzhang Cai; Kai Yuan; Lingyun Mei; Yong Feng
Journal:  Gene Ther       Date:  2021-02-25       Impact factor: 4.184

2.  Upregulation of the Nr2f1-A830082K12Rik gene pair in murine neural crest cells results in a complex phenotype reminiscent of Waardenburg syndrome type 4.

Authors:  Karl-F Bergeron; Chloé M A Nguyen; Tatiana Cardinal; Baptiste Charrier; David W Silversides; Nicolas Pilon
Journal:  Dis Model Mech       Date:  2016-09-01       Impact factor: 5.758

3.  Degeneration of saccular hair cells caused by MITF gene mutation.

Authors:  Yi Du; Li-Li Ren; Qing-Qing Jiang; Xing-Jian Liu; Fei Ji; Yue Zhang; Shuo-Long Yuan; Zi-Ming Wu; Wei-Wei Guo; Shi-Ming Yang
Journal:  Neural Dev       Date:  2019-01-11       Impact factor: 3.842

4.  The Hearing Outcomes of Cochlear Implantation in Waardenburg Syndrome.

Authors:  Hajime Koyama; Akinori Kashio; Aki Sakata; Katsuhiro Tsutsumiuchi; Yu Matsumoto; Shotaro Karino; Akinobu Kakigi; Shinichi Iwasaki; Tatsuya Yamasoba
Journal:  Biomed Res Int       Date:  2016-06-08       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.